Covered recipient · General Payments record
YUAN CHEN
Allopathic & Osteopathic Physicians Pain Medicine Interventional Pain Medicine
General Payments · PY2018–2024
$5,802.60
- Reported across 280 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $340.34 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $97.43 | 4 |
| PFIZER INC. | $91.55 | 4 |
| IBSA Pharma Inc. | $49.81 | 3 |
| SCILEX PHARMACEUTICALS INC. | $40.82 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $23.84 | 1 |
| Nevro Corp. | $23.58 | 1 |
| Bioventus LLC | $13.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.65 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103454338 | CMS |
| ABBVIE INC. | $29.53 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103454340 | CMS |
| ABBVIE INC. | $27.08 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103454342 | CMS |
| ABBVIE INC. | $25.17 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103454344 | CMS |
| Bioventus LLC | $13.31 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137438263 | CMS |
| Boston Scientific Corporation | $23.84 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092556442 | CMS |
| IBSA Pharma Inc. | $15.40 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142977770 | CMS |
| IBSA Pharma Inc. | $16.22 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142971736 | CMS |
| IBSA Pharma Inc. | $18.19 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142975459 | CMS |
| Nevro Corp. | $23.58 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130769214 | CMS |
| PFIZER INC. | $23.60 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131231009 | CMS |
| PFIZER INC. | $22.82 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131685258 | CMS |
| PFIZER INC. | $22.63 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131867760 | CMS |
| PFIZER INC. | $22.50 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132081894 | CMS |
| SCILEX PHARMACEUTICALS INC. | $18.08 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136268495 | CMS |
| SCILEX PHARMACEUTICALS INC. | $22.74 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136279216 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.